Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Epogen epoetin alfa regulatory update

FDA and AMGN released new labels for erythropoiesis-stimulating agents (ESAs) that recommend discontinuing ESA administration for any indication if a patient's hemoglobin (Hb) hits

Read the full 249 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE